Biofrontera Inc. (BFRI) Dividend Safety Gauge & 10-Year DRIP Compounder

BFRI scores 27 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 4/20 (ROIC -35%; FCF yield 0%); Whale 13F Flow at 6/20 (institutional accumulation and options positioning); Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit at 6/20 (Beta 1.0; sector sensitivity); and Forensic Balance Sheet at 8/20 (Altman Z 2.5; Piotroski F 3/9; Debt/Equity 0.5).

Taken together, the lowest-scoring pillars sit on the cash-generation and insider-signal sides. A 0% FCF yield and -35% ROIC mean the reported financials do not currently show the business converting capital into cash returns, and the insider pillar's low score means the source data contains little supportive insider behavior. The balance sheet pillar is the highest-scoring of the five, but at 8/20 it is still weak, with a Piotroski F-Score of 3/9. For a prospective investor, the upside case rests on operating improvement or external catalysts rather than on current cash generation or insider conviction. The valuation tradeoff is that a $0.93 price with a $13.

Biofrontera Inc. (BFRI) is listed on NASDAQ and classified under the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. The company reported revenue of $41.7M for FY 2025.

Revenue grew from $34.1M (FY 2023) to $41.7M (FY 2025), while net losses narrowed from -$20.1M to -$10.5M over the same span. Market data reports an operating margin of -27.2%, a net margin of -25.3%, a gross margin of 0%, and ROIC of -35%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 3/9, both 's forensic balance sheet pillar. Debt/Equity is 0.

• 🐂 Primary Bull Case: Revenue grew from $34.1M in FY 2023 to $41.7M in FY 2025 while net losses narrowed from -$20.1M to -$10.5M. With Fundamental Cash Engine at 4/20 (ROIC -35.0%, FCF yield —) and Institutional Whale Flow at 5/20, sustained execution supports upside toward the top of the $0.56 – $1.66 52-week range.
• 🐻 Primary Bear Case: Negative ROIC of -35% and a 0% FCF yield, with FY 2025 free cash flow of -$13.4M, show no current cash generation under the RQD cash-engine pillar. Investors must weigh current valuation against -27.2% operating margins and a 1.00 macro beta if sector demand softens.

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), BFRI carries a macro regime beta of 1.00 and gross margin of —.

• Key Question #1: What is the nature and timing of the Supplemental New Drug Application, and what product does it concern?
• Key Question #2: What are the reasons and implications of the Nasdaq notice regarding warrant listing or registration removal?
• Key Question #3: What are the reported debt levels, since the financial table lists debt as N/A?